Lv4
598 积分 2023-09-13 加入
[Clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version)]
12天前
已完结
Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial
1个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
1个月前
已完结
HER2-directed therapy improves urothelial cancer outcomes
2个月前
已完结
Megacystis microcolon intestinal hypoperistalsis syndrome: Case series and updated review of the literature with an emphasis on urologic management
3个月前
已完结
特发性腹膜后纤维化和IgG4相关性腹膜后纤维化诊治进展
4个月前
已完结
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
4个月前
已完结
Partial and radical cystectomy provides equivalent oncologic outcomes in bladder cancer when combined with adequate lymph node dissection: A population-based study
4个月前
已完结
Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings
4个月前
已完结
Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
4个月前
已完结
皖公网安备34019202002308
